Medifast Inc (MED) Quarterly Institutional 13F Update (Q2 2026)

MED ranks #4268 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

MED is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

116 institutions disclose a position in MED, but none treat it as a major bet — even Steamboat Capital Partners, LLC, its most concentrated holder, allocates just 1.6% of its own portfolio to it.

SummerHaven Investment Management, LLC has added to its MED position for two straight quarters, increasing it by $300.3K to reach $787.7K today.

MED is down 1.5% today, and institutions have been net sellers of $1.2M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

MED reported a net loss of $25.6M over the trailing twelve months.

• Not yet profitable — net loss of $25.6M over the trailing twelve months
• Revenue declined 34.0% year over year
• Net income declined year over year, from $3.6M to -$25.6M
• Generated $6.9M in positive operating cash flow
• Current ratio of 4.69x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.25x equity — within a conventional range